17 October 2024NewsAmericasMarisa Woutersen

LSPN Fall: Why Big Pharma is facing 'a balancing act'

As  the pharma sector grapples with legal and regulatory upheaval, LSPN Fall North America explored the need for companies to reassess their patent strategies. Marisa Woutersen reports.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
16 October 2024   UK biopharma company says US rival infringed patented mRNA technology I Moderna ‘touted speed’ of Spikevax development but used protected inventions, according to suit | Moderna reported over $6bn globally in 2023 from the Spikevax products.
Europe
9 October 2024   Roche’s chief trademark officer has more than filing and searches on his to-do list—and external counsel must keep up, he tells Marisa Woutersen.

More on this story

Americas
16 October 2024   UK biopharma company says US rival infringed patented mRNA technology I Moderna ‘touted speed’ of Spikevax development but used protected inventions, according to suit | Moderna reported over $6bn globally in 2023 from the Spikevax products.
Europe
9 October 2024   Roche’s chief trademark officer has more than filing and searches on his to-do list—and external counsel must keep up, he tells Marisa Woutersen.

More on this story

Americas
16 October 2024   UK biopharma company says US rival infringed patented mRNA technology I Moderna ‘touted speed’ of Spikevax development but used protected inventions, according to suit | Moderna reported over $6bn globally in 2023 from the Spikevax products.
Europe
9 October 2024   Roche’s chief trademark officer has more than filing and searches on his to-do list—and external counsel must keep up, he tells Marisa Woutersen.